Will Morton

[email protected]

AI devices vary widely in lung cancer detection

Three devices helped detect more cancerous tumors, whereas the other four devices helped detect fewer tumors.

May 19, 2026

Cropped secondary capture examples. These are illustrative and not intended to imply superiority or inferiority of any device. (A) Posteroanterior radiograph in a 46-year-old female patient. The device correctly identified a right lower lobe nodule projected below the right hemidiaphragm and hilar lymphadenopathy. (B) Posteroanterior radiograph in an 86-year-old female patient with a classic Golden S sign highly suggestive of cancer. Three devices did not identify any findings. (C) The output from one device for the same radiograph as in B. The device placed a contour around the area of abnormality but mislabeled it as segmental collapse, and there are no other elements in the output to raise suspicion of cancer. (D) Posteroanterior radiograph in a 60-year-old male patient -- a case of confirmed lung cancer that was not deemed visible in retrospect. The device identified multiple false-positive abnormalities. (E) Posteroanterior radiograph in a 77-year-old female patient with two right lower lobe nodules. The device mislabeled the abnormality as infection -- a diagnostic term that could incorrectly influence clinical management. (F) Posteroanterior radiograph in a 77-year-old female patient with a right hilar tumor. Most of the lungs have been labeled by the device, with excessive overlap of the abnormality that pragmatically represents an incorrect result. All annotations shown were produced by the devices. LL = lung lesion, LO = lung opacity, PO = pleural other, TBC = tuberculosis.

Combined fluoride and lead exposure reduces bone health in youth

Co-exposure to fluoride and lead exacerbates changes in BMD more than single exposure, suggesting synergistic effects on bone impairment.

May 18, 2026

A graphical abstract of the study.

ISMRM: Functional lung MRI detects asthma treatment responses

Biologic treatment of severe eosinophilic asthma is successful in only 80% of patients and predictive factors for treatment response are not yet available.

May 11, 2026

Representative PREFUL and F-19 MRI results at baseline and three months of a male responder (age: 47). First row: PREFUL ventilation images; Second row: Ventilation defect percentage (VDP) maps; Third row: Flow-volume loop (FVL) maps. VDP changed from 54% to 23% and the FVL score over the whole lung increased from 88% to 98%. Fourth and fifth rows: second breath-hold F-19 ventilation with corresponding VDP map; sixth and seventh rows: sixth breath-hold F-19 ventilation with corresponding VDP map. Second VDP decreased from 26% to 10% and 6th VDP from 16% to 3%.

ISMRM: Whole-body MRI links visceral fat to prostate enlargement

Each 1,000-mL increase in visceral fat volume was associated with higher adjusted odds of prostate enlargement.

May 9, 2026

Ismrm Thumbnail

DEXA confirms benefits of soccer on bone health

Players underwent a DEXA scan at the start of the season, at four months, and again at nine months.

May 8, 2026

Adobe Stock 1624861495

LLMs excel at scoliosis detection on spine x-rays

For scoliosis detection, Grok 4 led with 94.2% accuracy.

May 7, 2026

Molecular Imaging

PSMA-PET linked to higher use of systemic therapies

ARPI therapy was initiated in 15.6% of PSMA-PET patients versus 7.7% of bone scan patients.

May 7, 2026

Radiation segmentectomy can be optimized before liver transplant

As of 2023, yttrium 90 (Y-90) radioembolization has become the most frequently used local-regional therapy in the U.S. for bridging patients with HCC to liver transplant.

May 5, 2026

Illustrations show the role of angiosome-to-tumor volume ratio (ATR) in different clinical scenarios based on tumor and treatment angiosome volume. The pale orange oval represents the tumor within the liver, and the pie-shaped region encompassed by the black lines represents the angiosome. (A) An adequate ATR (≥16) is reached when treating tumor and an accompanying appropriate volume of expendable surrounding normal parenchyma, such as a 2.5-cm tumor within a 150-mL treatment angiosome. Lower (inadequate) ATR can occur with superselective administrations, such as (B) attempting to treat a larger (4-cm) tumor within the same 150-mL angiosome, which proves suboptimal, and (C) attempting to treat the same 2.5-cm tumor within a reduced angiosome (40 mL).

Radiation Oncology/Therapy

Will upright radiotherapy become a new standard?

Multiple commercial upright systems have entered the market in recent years.

May 4, 2026

Molecular Imaging

NET tracers first widened, then closed imaging access gap

Ga-68 DOTATATE/DOTATOC captured 33.8% market share in its 2017 debut and reached 90.9% by 2020.

April 30, 2026

Adobe Stock 107601498

Page 2 of 53

Cardiac stress test imaging comparison showing DeepAC and CT-based attenuation correction scans for two patients with quantitative perfusion data.

AI-driven cardiac PET attenuation correction shows promise

The algorithm could offer a “practical alternative in cardiac PET,” researchers noted.

Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).

Image-guided focal laser ablation effective for prostate cancer

Asco Thumb

ASCO: With help from AI, interventions boost lung cancer screening

2260299 Philips 01 Aunt Minnie Leadgen Newsletter Banner 300x250 Static

Philips Interactive Multimedia Reporting: Where Insight Meets Impact

David Vining Md Anderson Longitudinal Record Imr 2026

Radiologists estimate time savings with advanced radiology reports

SNMMI: Theranostic approach may treat PSMA-negative prostate cancer

By Amerigo Allegretto

A theranostic approach could help improve PET imaging for neuroendocrine prostate cancer care.

June 2, 2026

RET-targeted PET tracer highlights neuroendocrine prostate cancer tumors. Representative PET imaging shows strong tumor uptake of the RET-binding peptide tracer [⁶⁸Ga]Ga-DOTA-RET-L7 in a neuroendocrine prostate cancer (NEPC) model, supporting highly specific, high-contrast detection.

ASCO: Use of GLP-1 drugs linked to lower breast cancer cases

By Erik L. Ridley

A large retrospective study found sharply lower incidence of breast cancer among women who had received GLP-1 drugs.

June 2, 2026

SNMMI: CAIX-targeted PET tracer detects clear cell renal cell carcinoma

Researchers aim for "more precise molecular map" for kidney cancer.

June 1, 2026

A 68Ga-RCC78 PET scan (C) of a patient four years post-radical right nephrectomy. During follow-up, new nodules were detected in the left adrenal gland and kidney. CAIX-targeted scan clearly visualized metastatic lesions in the mediastinum, pancreas, adrenal gland, and kidney (SUVmax > 30), demonstrating the tracer's ability to maintain high tumor uptake despite significantly reduced abdominal background.

SNMMI: Low-cost absorbents clear over 90% of Lu-177 from wastewater

By Kate Madden Yee

An increase in the use of radionuclide therapy has added burden to wastewater management systems.

June 1, 2026

SNMMI: PET tracer that detects deep vein thrombosis wins Image of the Year

F-18 GP1 is derived from elarofiban and selectively binds to glycoprotein IIb/IIIa receptors on activated platelets.

June 1, 2026

(Left) F-18 GP1 PET/CT images from a 75-year-old woman show multiple blood clots in the deep veins of the left leg (from the thigh to the calf), as well as several clots in the right calf. Venous ultrasound confirms blood clots in left thigh, knee and calf veins. PET/CT also detects clots in both lungs, which are confirmed by contrast-enhanced CT image. (Right) 18F-GP1 PET/CT images from a 70-year-old woman show widespread blood clots throughout the body. In addition to clots in the deep veins of both legs and the arteries of both lungs (A), the scan also detected unexpected clots in several other areas, including blood vessels near the skull/head (B), spine (C), heart (D), and pelvis (E). Further evaluation revealed that the patient had antiphospholipid syndrome, an autoimmune condition that increases the risk of abnormal blood clot formation.

SNMMI: Novel radiotracer effectively images overactive adrenal glands

University of Michigan researchers report on first-in-human study of SOAT1-targeted nevanimibe C-11.

June 1, 2026

Static PET-CT image of patient with hypercortisolism taken at 60 minutes post-injection.

SNMMI: Mouaz Al-Mallah discusses cardiac PET

In this interview, Mouaz Al-Mallah, MD, discusses cardiac PET imaging, including new efforts to create more access for patients and the impact of new radiotracers.

June 1, 2026

Mouaz Al Mallah Thumb1

ASCO: Proton therapy, IMRT both work well for prostate cancer

By Erik L. Ridley

Both modalities yielded similar outcomes, according to preliminary results from a large, prospective trial.

June 1, 2026

SNMMI: Point-of-care PET system may guide interventional procedures

By Amerigo Allegretto

A portable, point-of-care PET system showed success in imaging organs and may be helpful in interventional guidance.

June 1, 2026

(a) Benchtop portable POC-PET prototype system. (b) Phantom imaging experiment setup. (c) Comparison of conventional full-data MLEM reconstruction with incremental OSEM reconstruction.

SNMMI: Brain-dedicated PET scanner cuts claustrophobia, boosts comfort

By Kate Madden Yee

The findings "support the use of brain-dedicated PET scanners as a patient-centered alternative," researchers wrote.

June 1, 2026

SNMMI: PET tracer detects CTE tau pathology in living patients

By Kate Madden Yee

Study findings suggest "a clinical role for PET in traumatic brain injury and sports- and military-related neurodegeneration."

May 31, 2026

Parametric maps obtained with SRTM2 (cerebellum grey matter as reference) for the group of healthy participants (top) and from one representative participant with suspected CTE (bottom). CTE: chronic traumatic encephalopathy.

SNMMI: SPECT/CT tracer shows promise in interstitial lung disease

Differentiating between fibrotic scarring and inflammation stages of disease is critical so that physicians can determine what treatment is best for the patient.

May 31, 2026

Sample images from each participant group: A: CT only; B: fused Tc-99m maraciclatide SPECT/CT.

Page 2 of 231